Terms: = Brain cancer AND HER1, YOR227W AND Treatment
17 results:
1. Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
[TBL] [Abstract] [Full Text] [Related]
2. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
3. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
5. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract] [Full Text] [Related]
6. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?
Göksu SS; Bozcuk H; Koral L; Çakar B; Gündüz S; Tatlı AM; Arslan D; Uysal M; Koçer M; Artaç M; Karabulut B; Coşkun HS; Özdoğan M; Savaş B
Indian J Cancer; 2015; 52(4):517-9. PubMed ID: 26960462
[TBL] [Abstract] [Full Text] [Related]
7. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract] [Full Text] [Related]
8. Combined inhibition of her1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G; Westhoff MA; Zhou S; Nonnenmacher L; Dwucet A; Kast RE; Bachem MG; Wirtz CR; Debatin KM; Halatsch ME
Mol Cancer Ther; 2013 Sep; 12(9):1783-95. PubMed ID: 23832120
[TBL] [Abstract] [Full Text] [Related]
9. Subacute transient encephalopathy induced by erlotinib.
Okyuama T; Akazawa Y; Uchida J; Nishino K; Kumagai T; Imamura F
Oncol Res; 2011; 19(8-9):399-402. PubMed ID: 22329199
[TBL] [Abstract] [Full Text] [Related]
10. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract] [Full Text] [Related]
11. Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Karpel-Massler G; Wirtz CR; Halatsch ME
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):384-94. PubMed ID: 21612575
[TBL] [Abstract] [Full Text] [Related]
12. Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/her1-negative breast cancer.
Onishi H; Morisaki T; Nakafusa Y; Nakashima Y; Yokohata K; Katano M
Int J Clin Oncol; 2011 Dec; 16(6):718-21. PubMed ID: 21327450
[TBL] [Abstract] [Full Text] [Related]
13. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract] [Full Text] [Related]
14. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract] [Full Text] [Related]
15. brain metastases from breast cancer: management approach.
Wadasadawala T; Gupta S; Bagul V; Patil N
J Cancer Res Ther; 2007; 3(3):157-65. PubMed ID: 18079579
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract] [Full Text] [Related]
17. her1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract] [Full Text] [Related]
